Six weeks after STAT News reported Lilly’s retatrutide compassionate use of a single unnamed 79-year-old man through the FDA’s expanded access pathway, the Indianapolis drugmaker on Monday confirmed it has built a formal program — and set four eligibility criteria that most Americans with obesity will not be able to satisfy. The announcement, which came after STAT inquired about a handful of physician requests that had gone unanswered, marks a step toward transparency from a company that had been largely silent about its compassionate use arrangements. But the criteria themselves tell a more complicated story about who actually gets access to the most anticipated obesity drug in development.
Lilly’s Four Criteria, Explained
To receive retatrutide through the program, a patient must satisfy all four conditions simultaneously. Reuters confirmed all four criteria from a Lilly spokesperson statement on Monday
The patient must be 18 or older. That condition is unremarkable. The remaining three are where the bar rises sharply
The patient must have refractory obesity despite tolerating the highest approved dose of obesity therapy. In practice, this means the patient must have been treated with tirzepatide (Zepbound) at its maximum approved dose of 15 mg weekly — or another approved anti-obesity agent at its maximum dose — and still have insufficient weight loss. The phrase “tolerating the highest approved dose” is itself clinically ambiguous: patients who experienced severe nausea or dysesthesia at high doses and were stepped down occupy a different category from patients who completed maximum-dose treatment and simply didn’t respond, a distinction documented in a March 2026 clinical review of anti-obesity therapy failure.
The patient must have at least two serious or life-threatening obesity-related complications for which they are actively receiving care. These are not theoretical comorbidities — they must be documented conditions being treated by named physicians. Conditions that qualify would typically include pulmonary hypertension, severe obstructive sleep apnea, advanced non-alcoholic steatohepatitis, or serious cardiovascular disease directly attributable to obesity
The patient must be unable to enroll in an ongoing clinical trial of retatrutide or a comparable investigational drug. Given that Eli Lilly’s TRIUMPH program currently includes multiple actively enrolling studies across a range of indications, this criterion means the patient has been screened and found ineligible for all of them — or lives beyond practical reach of any participating site
Meeting all four conditions at once describes a clinical profile that is genuinely uncommon. This is not a patient who is frustrated with their Zepbound results and wants something more effective. This is a patient who has failed maximal pharmacotherapy, is managing two or more documented life-threatening complications, and cannot access a trial. The program’s eligible population is likely in the hundreds to low thousands nationally — not the hundreds of millions who want retatrutide and cannot yet have it.
What the Program Solves — and What It Doesn’t
Lilly’s announcement represents a meaningful departure from the single-patient arrangement that triggered the June controversy. The original access arrangement involved one patient, no publicly described eligibility criteria, and a process that drew the attention of senior government health officials — details that prompted medical ethicists and clinicians to question whether it cleared the standard threshold for compassionate use
The new program creates at least three things the prior arrangement lacked: formal criteria that are publicly describable, a process by which any physician can submit a request through Lilly’s medical affairs team, and an acknowledgment from Lilly that such access is appropriate for a defined patient population
What the program does not create: a legal obligation for Lilly to approve any particular request; an independent oversight body reviewing the equity of who is selected; a public reporting mechanism for how many requests are received, approved, or denied; or access for the vast majority of the 100 million Americans with obesity who are waiting for retatrutide to reach pharmacy shelves
Under existing federal law, the FDA allows 99% of all expanded access requests to proceed — meaning the agency has never been the limiting factor. The drug company is the gating authority. The 21st Century Cures Act requires pharmaceutical companies to publicly post expanded access policies, but it does not compel them to act on any request. Lilly’s decision to provide or deny retatrutide to any individual patient remains, in law, entirely within the company’s discretion
Why Five Completed Trials Haven’t Unlocked Pharmacy Access
Retatrutide’s clinical case for approval is unusually strong. As of late July 2026, the drug has produced positive results in five Phase 3 trials:
TRIUMPH-1 (May 21, 2026): Participants on the highest dose (12 mg weekly) achieved 28.3% average weight loss — approximately 70 pounds — over 80 weeks, across 2,339 participants. Nearly half (45.3%) lost 30% or more, a benchmark previously achievable only through bariatric surgery
TRIUMPH-4 (December 2025): Patients with obesity and knee osteoarthritis achieved 28.7% body weight reduction at 68 weeks alongside dramatic reductions in joint pain
TRANSCEND-T2D-1 (March 2026): Adults with type 2 diabetes achieved an HbA1c reduction of 2.0 points alongside 16.8% weight loss
TRIUMPH-2 (July 23, 2026): Adults with obesity and type 2 diabetes on the highest dose achieved 20.8% weight loss at 80 weeks — roughly 50 pounds
TRIUMPH-3 (July 23, 2026): Adults with severe obesity and established cardiovascular disease achieved 22.6% weight loss at 80 weeks, or about 56 pounds (25.4 kg), alongside improvements in triglycerides, non-HDL cholesterol, blood pressure, and inflammatory markers
None of that clinical success translates to pharmacy access today. On July 23, Lilly confirmed it plans BLA submission for Q1 2027 — the Biologics License Application pathway for biologically derived compounds, which retatrutide qualifies as. After BLA submission, the FDA typically takes 10 to 12 months to complete its review; with Priority Review designation, the window compresses modestly. The most realistic window for FDA approval is late 2027 to early 2028, with commercial availability following months after that.
Read more:Eli Lilly’s Retatrutide Matches Bariatric Surgery: 30% Weight Loss in Phase 3 Trial
The Gray Market Has Not Waited
While clinical development has proceeded and the expanded access program has now been formalized, millions of Americans have not waited for either. A CBS News investigation documented more than 120 websites and over 50 clinics across the United States actively selling or promoting retatrutide without FDA approval. Human exposures to unregulated retatrutide reported to US poison control centers averaged 95 monthly cases in the first four months of 2026 — a 265% increase from the final months of 2025.
The FDA has issued more than 14 warning letters to retatrutide vendors since December 2024. As of May 2026, 11 of those companies were still advertising the drug and 8 were still actively selling it, according to a Public Citizen Medscape investigation. Enforcement has stalled at the warning-letter stage, with the FDA lacking the reustice coordination
Retatrutide cannot be legally compounded under federal law. Unlike semaglutide (Wegovy) and tirzepatide (Zepbound), which were compounded during shortage periods because they are components of approved drug products, retatrutide has no approved version, no USP monograph, and does not appear on the FDA’s bulk substance lists. No compounding exemption applies
Products sold online as retatrutide — typically labeled “for research purposes only” or “not for human consumption” — carry no guarantees of purity, potency, or sterility. The FDA has documented GLP-1 peptide contamination including heavy metals, endotoxins, and incorrect peptide sequences in unregulated samples. In clinical trials conducted under full medical supervision, nausea occurred in 42.4% of participants on the highest dose and dysesthesia — an abnormal, often painful skin-sensation disorder — appeared in 12.5% of participants. Patients obtaining the drug through gray-market sources face those risks without dose-escalation protocols, medical oversight, or any avenue for recourse.
Why “Authentic Retatrutide” Is Also a Business Message
Lilly’s August 3 statement described the program as making “authentic retatrutide” available to qualifying patients. That word choice is not accidental. It positions Lilly’s formally administered drug against gray-market materials that may be mislabeled, contaminated, or outright counterfeit — and it communicates to gray-market vendors and their customers that the company has a stake in the identity of what reaches patients
The program is, in this sense, a dual-purpose announcement: a public health measure and a brand-protection signal. Whether that makes it more or less trustworthy as a patient equity mechanism is a judgment each physician making a request will need to reach independently
What Comes Next — and When
With a BLA filing confirmed for Q1 2027, the path to standard pharmacy access is now the clearest it has ever been:
Q1 2027: Lilly plans to submit a BLA to the FDA. The agency has 60 days to accept the filing and assign a PDUFA review date
Late 2027 to early 2028: Expected FDA approval window, assuming no unexpected safety signals from ongoing trials (including TRIUMPH-5, a head-to-head comparison against tirzepatide currently enrolling, with results expected December 2026, and TRIUMPH-Outcomes, a long-term cardiovascular and kidney outcomes trial)
2028 or later: Realistic commercial availability. Lilly has indicated retatrutide is expected to sit above Zepbound as a premium tier within its obesity portfolio, suggesting a list price above $1,000 per month before insurance negotiations. The Medicare GLP-1 Bridge program — which covers Wegovy, Zepbound, and Foundayo (orforglipron) at a capped cost of $50 per month for eligible beneficiaries — covers only FDA-approved drugs; retatrutide will not be eligible until FDA approval is granted
Until that window arrives, the formal expanded access program will serve as a narrow legal channel between the gray market’s hazards and the pharmacy’s inaccessibility. For the patients who meet all four criteria, it offers supervised access to a drug that may have no approved equivalent. For most of the 100 million Americans with obesity who want it, the choice between waiting and assuming the risks of unregulated channels remains unchanged
Frequently Asked Questions
Does Lilly’s new expanded access program mean I can get retatrutide?
Only if you meet all four criteria simultaneously: you must be 18 or older, have refractory obesity despite reaching the highest approved dose of an existing obesity therapy, have at least two serious or life-threatening obesity-related complications for which you are actively receiving care, and be ineligible for any ongoing clinical trial of retatrutide. All four conditions must be met concurrently. For patients who are frustrated with current weight-loss medication results but do not have two documented life-threatening complications, the criteria will not be met. Physicians submit requests to Lilly; patients cannot apply directly.
When will retatrutide be available at a regular pharmacy?
Eli Lilly confirmed on July 23, 2026, that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. After submission, FDA review typically takes 10 to 12 months. Under realistic timelines, FDA approval is expected in late 2027 to early 2028, with commercial launch following several months after approval. The earliest a patient could fill a standard pharmacy prescription would be 2028. Existing approved options — Zepbound and Foundayo obesity drugs, which include tirzepatide (Zepbound) at up to 22.5% average weight loss and orforglipron (Foundayo) at $149 per month at the starting dose — remain the only approved alternatives in the meantime.
What is the difference between Lilly’s expanded access program and buying retatrutide online?
The difference is legal status, safety, and oversight. Lilly’s program provides pharmaceutical-grade retatrutide — the same compound used in Phase 3 trials — under a physician’s supervision, with dose escalation protocols and medical monitoring. Products sold online as retatrutide are unregulated: they may be mislabeled, contaminated, or counterfeit. The FDA has documented heavy metals, endotoxins, and incorrect peptide sequences in unregulated peptide products. Poison control centers recorded a 265% surge in retatrutide exposure cases in early 2026. Retatrutide cannot be legally compounded — any online vendor selling it is operating outside federal law.
Who actually controls who gets access to experimental drugs in the US?
The pharmaceutical manufacturer does — not the FDA. The FDA allows nearly all requests — over 99% of expanded access requests it receives; the agency almost never declines. The decision about whether to provide a drug to any individual patient belongs entirely to the company. Under current federal law, no manufacturer is legally required to provide an investigational drug to any patient. The 21st Century Cures Act requires companies to publicly post their expanded access policies, but it does not compel them to honor any request. There is no public oversight body that audits who is selected, how many requests are received, or what criteria different applicants are held to.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission
Tags:FDA
